首页 / 产品 / 抗体 / 一抗

Rat Monoclonal Cmtm6 Antibody

  • 中文名: Cmtm6抗体
  • 别    名: nan
货号: IPDX15807
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Mouse, Human
IF 咨询技术 Mouse, Human
IHC 1/20-1/100 Mouse, Human
ICC 技术咨询 Mouse, Human
FCM 咨询技术 Mouse, Human
Elisa 咨询技术 Mouse, Human

产品详情

Host/IsotypeRat IgG2a
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityMouse, Human
ImmunogenPurified recombinant fragment of mouse Cmtm6
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

参考文献

以下是3篇关于Cmtm6抗体的参考文献概览:

1. **"Cmtm6 maintains the expression of PD-L1 and regulates anti-tumour immunity"**

*作者:Burr et al. (Nature, 2017)*

摘要:首次揭示Cmtm6通过结合PD-L1并阻止其溶酶体降解,维持肿瘤细胞表面PD-L1蛋白稳定性,为免疫检查点抑制剂的耐药机制提供新解释,研究中使用了Cmtm6抗体进行免疫共沉淀实验。

2. **"CMTM6 modulates PD-L1 expression by antagonizing EGFR-mediated ubiquitination in melanoma"**

*作者:Yang et al. (Cancer Research, 2021)*

摘要:证明Cmtm6通过抑制EGFR对PD-L1的泛素化降解通路增强其表达,研究中采用Cmtm6特异性抗体进行免疫荧光染色,揭示其在黑色素瘤微环境中的空间表达模式。

3. **"CRISPR screens identify CMTM6 as a therapeutic target in PD-L1-positive cancers"**

*作者:Jiang et al. (Cell Reports, 2020)*

摘要:通过CRISPR筛选发现Cmtm6是PD-L1阳性肿瘤的潜在治疗靶点,研究使用Cmtm6抗体验证基因敲除后PD-L1蛋白水平下降,并证明联合抗Cmtm6与PD-1抑制剂可增强抗肿瘤效果。

*注:以上文献均为肿瘤免疫治疗领域的高影响力研究,Cmtm6抗体主要用于机制验证实验(如WB、IP、IF),尚未见直接针对Cmtm6的治疗性抗体开发文献。*

背景信息

Cmtm6 (CKLF-like MARVEL transmembrane domain-containing 6) is a protein involved in regulating the stability and membrane localization of programmed death-ligand 1 (PD-L1), a key immune checkpoint molecule exploited by cancer cells to evade immune surveillance. Discovered as part of the MARVEL domain-containing protein family, Cmtm6 interacts with PD-L1 to prevent its lysosomal degradation, thereby enhancing its immunosuppressive function in the tumor microenvironment. Antibodies targeting Cmtm6 have emerged as valuable tools to study this regulatory mechanism, offering insights into PD-L1 dynamics and potential therapeutic strategies. These antibodies are commonly used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect Cmtm6 expression in cell lines, tissues, or tumor samples. Research leveraging Cmtm6 antibodies has highlighted its role in cancer immunology, particularly in modulating anti-tumor immune responses. By disrupting Cmtm6-PD-L1 interactions, scientists aim to develop approaches to reduce PD-L1-mediated immune evasion, potentially enhancing the efficacy of cancer immunotherapies like anti-PD-1/PD-L1 treatments. Cmtm6 antibodies also serve as diagnostic tools to explore correlations between Cmtm6 expression levels, PD-L1 status, and clinical outcomes in various cancers.

客户数据及评论

折叠内容

大包装询价

×